Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery

Area of Science:

• Biochemistry
• Oncology
• Proteomics

Background:

• Ovarian cancer is a leading cause of cancer death globally.
• Current diagnostic methods lack sufficient sensitivity, contributing to high mortality rates.
• Early detection through reliable biomarkers is crucial for improving patient outcomes.

Purpose of the Study:

• To identify novel blood-based protein biomarkers for early ovarian cancer detection.
• To evaluate the diagnostic performance of these potential biomarkers.
• To explore their role in ovarian cancer molecular pathways.

Main Methods:

• Utilized isobaric Tags for Relative and Absolute Quantification (iTRAQ) labeling coupled with mass spectrometry.
• Analyzed serum samples from patients with ovarian cancer, benign ovarian tumors, and healthy controls.
• Validated differentially expressed proteins through further analysis.

Main Results:

• Identified five differentially expressed proteins in ovarian cancer patients: Serotransferrin, Amyloid A1, Hemopexin, C-reactive protein, and Albumin.
• Demonstrated that adding Albumin, Serotransferrin, and Amyloid A1 to CA125 and HE4 improved the discrimination between benign and malignant ovarian tumors.
• These proteins offer insights into molecular signaling pathways involved in ovarian cancer.

Conclusions:

• The five identified proteins show significant potential as biomarkers for ovarian cancer screening and detection.
• A multi-marker test incorporating these proteins could enhance diagnostic accuracy.
• Further investigation into these proteins and their associated pathways is warranted.